melatonin has been researched along with Stroke in 61 studies
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We explored the potential efficacy of melatonin in the treatment of patients with acute ischemic stroke." | 9.51 | Melatonin supplementation may benefit patients with acute ischemic stroke not eligible for reperfusion therapies: Results of a pilot study. ( Ahmadimoghaddam, D; Khazaie, M; Mazdeh, M; Mehrpooya, M; Rahmani, E, 2022) |
| "To assess an effect of melatonin on quality of life and effectiveness of rehabilitation in patients with ischemic stroke (IS) suffered from insomnia due to sleep initiation disturbance." | 9.20 | [Melatonin in the correction of sleep in post-stroke patients]. ( Davidov, NP; Ivanova, DS; Kuznetsov, AN; Vinogradov, OI, 2015) |
| " The purpose of this study was to evaluate the effect of fluvoxamine maleate, a selective serotonin re-uptake inhibitor (SSRI), on depressive state, sleep disturbance, and serum melatonin levels in patients with depressive state after cerebral infarction." | 9.16 | A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction. ( Katayama, Y; Katsura, K; Nishiyama, Y; Otori, T; Sunami, E; Usuda, K, 2012) |
| "Delivery of melatonin and targeting melatonin receptors pose as neuroprotective strategies for stroke therapy." | 8.91 | An update on the use of melatonin as a stroke therapeutic. ( Aguirre, D; Borlongan, CV; Gonzales-Portillo, GS; Kaneko, Y; Lozano, D; Reyes, S; Tajiri, N, 2015) |
| "The present review paper supports the approach to deliver melatonin and to target melatonin receptors for neuroprotection in stroke." | 8.89 | Melatonin-based therapeutics for neuroprotection in stroke. ( Borlongan, CV; Shinozuka, K; Staples, M, 2013) |
| "This article summarizes the evidence that endogenously produced and exogenously administered melatonin reduces the degree of tissue damage and limits the biobehavioral deficits associated with experimental models of ischemia/reperfusion injury in the brain (i." | 8.82 | When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. ( Kilic, E; Kilic, U; Leon, J; Reiter, RJ; Tan, DX, 2005) |
| "Melatonin is a candidate neuroprotective drug for ischaemic stroke." | 8.82 | Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. ( Donnan, GA; Horky, LL; Howells, DW; Macleod, MR; O'Collins, T, 2005) |
| "This review summarizes the numerous reports that have documented the neuroprotective actions of melatonin in experimental models of ischemia/reperfusion injury (stroke)." | 8.82 | Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke. ( Lopez-Burillo, S; Manchester, LC; Mayo, JC; Reiter, RJ; Sainz, RM; Tan, DX, 2003) |
| "Melatonin has a role in the cell survival signaling pathways as a candidate for secondary stroke prevention." | 8.12 | Delayed Therapeutic Administration of Melatonin Enhances Neuronal Survival Through AKT and MAPK Signaling Pathways Following Focal Brain Ischemia in Mice. ( Altug-Tasa, B; Beker, M; Beker, MC; Caglayan, AB; Elibol, B; Kilic, E; Kilic, U; Uysal, O; Yilmaz, B, 2022) |
| "Melatonin is a potent neuroprotective agent which has shown therapeutic effects in animal models of brain injury such as stroke." | 8.12 | Photothrombotic Mouse Models for the Study of Melatonin as a Therapeutic Tool After Ischemic Stroke. ( Cambiaghi, M; Cherchi, L; Comai, S, 2022) |
| "Consecutive patients admitted to the Tübingen University Stroke Unit, Tübingen, Germany, with acute ischemic stroke (AIS), who underwent standard care between August 2017 and December 2017, and patients who additionally received prophylactic melatonin (2 mg per day at night) within 24 h of symptom onset between August 2018 and December 2018 were included." | 8.02 | Delirium REduction after administration of melatonin in acute ischemic stroke (DREAMS): A propensity score-matched analysis. ( Boßelmann, C; Brendel, B; Fleischmann, R; Meisel, A; Mengel, A; Poli, S; Sartor-Pfeiffer, J; Stadler, V; Stefanou, MI; Ziemann, U; Zurloh, J, 2021) |
| "Previous literature has shown that melatonin plays a critical role in protecting against cerebral ischemia/reperfusion (I/R) injury." | 7.91 | Melatonin ameliorates cerebral ischemia/reperfusion injury through SIRT3 activation. ( Chen, H; Jin, J; Li, G; Liu, L; Tang, Z; Yin, P; Zhong, D, 2019) |
| " In this study, we examined diurnal rhythmicity in different stages of Huntington (HD) disease and in patients with acute moderate ischemic stroke (AIS) outside the retinohypothalamic pathway by evaluating serum concentrations of melatonin and cortisol at twelve timepoints." | 7.85 | Circadian rhythms of melatonin and cortisol in manifest Huntington's disease and in acute cortical ischemic stroke. ( Adamczak-Ratajczak, A; Checinska-Maciejewska, Z; Gibas-Dorna, M; Krauss, H; Kupsz, J; Michalak, S; Owecki, M; Sowinska, A; Zielonka, D, 2017) |
| "In the acute phase of ischemic stroke 73 patients aged from 61 to 86 years and 47 patients aged 36 to 60 years underwent a comprehensive neuropsychological testing, evaluation of the concentration of 6-sulfatoximelatonin 6-sulfatoximelatonin in the night urine and brain MRI morphometry in some patients." | 7.83 | [The role of melatonin in the development of post-stroke cognitive impairment in elderly patients in comparison with middle-aged patients]. ( Drobakha, VE; Kulesh, AA; Shestakov, VV, 2016) |
| "Melatonin at 60 min post ischemia rendered neuroprotection as evident by reduction in cerebral infarct volume, improvement in motor and neurological deficit and reduction in brain edema." | 7.80 | Melatonin renders neuroprotection by protein kinase C mediated aquaporin-4 inhibition in animal model of focal cerebral ischemia. ( Bhattacharya, P; Pandey, AK; Patnaik, R; Paul, S, 2014) |
| "The content of 6-sulfatoximelatonin in daily urine and butyrylcholinesterase in blood serum was determined in the acute stage of ischemic stroke in 25 and 40 men, respectively." | 7.78 | [Secretion of melatonin and serum cholinesterase activity as biological markers of cognitive disorders in the acute stage of ischemic stroke]. ( Kulesh, AA; Shestakov, VV, 2012) |
| "Melatonin has many protective effects against ischemic stroke, but the underlying neuroprotective mechanisms are not fully understood." | 7.78 | Melatonin ameliorates neural function by promoting endogenous neurogenesis through the MT2 melatonin receptor in ischemic-stroke mice. ( Chern, CM; Liao, JF; Shen, YC; Wang, YH, 2012) |
| "The efficacy of melatonin treatment in experimental stroke has been established." | 7.77 | Melatonin treatment following stroke induction modulates L-arginine metabolism. ( Appleton, I; Clarkson, AN; Nair, SM; Rahman, RM; Sammut, IA; Sutherland, BA; Taurin, S, 2011) |
| "Quantitative data on melatonin in stroke patients are scarce." | 7.75 | Impaired nocturnal melatonin in acute phase of ischaemic stroke: cross-sectional matched case-control analysis. ( Atanassova, PA; Dimitrov, BD; Terzieva, DD, 2009) |
| "Melatonin attenuates the short-term consequences of brain ischemia in several animal models." | 7.74 | Chronic and acute melatonin effects in gerbil global forebrain ischemia: long-term neural and behavioral outcome. ( de Butte, M; Fréchette, M; Pappas, BA; Rennie, K, 2008) |
| "Very little is known regarding melatonin's circadian rhythm in stroke patients." | 7.71 | Melatonin rhythms in stroke patients. ( Beloosesky, Y; Grinblat, J; Grosman, B; Laudon, M; Streifler, JY; Zisapel, N, 2002) |
| "Small doses of melatonin were administrated to 30 patients with day/night rhythm disorders, after cerebral stroke." | 7.70 | [Melatonin in sleep rhythm disorders after cerebral stroke]. ( Domzał, TM; Kaca-Oryńska, M; Zaleski, P, 2000) |
| "Ischemic stroke has remained a principal cause of mortality and neurological disabilities worldwide." | 6.72 | Effect of Melatonin on Endoplasmic Reticulum-Mitochondrial Crosstalk in Stroke. ( Abolhasanpour, N; Alihosseini, S; Badalzadeh, R; Golipourkhalili, S; Hosseini, L; Mahmoudi, J, 2021) |
| "Ischemic stroke is a leading cause of mortality and morbidity worldwide, with neuroinflammation playing a key role in its pathophysiology." | 5.91 | Melatonin regulates microglial polarization and protects against ischemic stroke-induced brain injury in mice. ( He, T; Li, D; Liu, J; Wang, D; Wang, Q; Yuan, Y; Zhang, S; Zhang, Y; Zhao, H, 2023) |
| "Melatonin has been shown to be neuroprotective in experimental stroke models." | 5.51 | Melatonin protects against ischemic stroke by modulating microglia/macrophage polarization toward anti-inflammatory phenotype through STAT3 pathway. ( Ding, ZT; Gao, FH; Gong, WJ; Liu, ZJ; Qie, SY; Ran, YY; Xi, JN, 2019) |
| "We explored the potential efficacy of melatonin in the treatment of patients with acute ischemic stroke." | 5.51 | Melatonin supplementation may benefit patients with acute ischemic stroke not eligible for reperfusion therapies: Results of a pilot study. ( Ahmadimoghaddam, D; Khazaie, M; Mazdeh, M; Mehrpooya, M; Rahmani, E, 2022) |
| "Melatonin was intraperitoneally administered to adult gerbils after transient global cerebral ischemia (tGCI) for 25 days beginning 5 days after tGCI." | 5.48 | Melatonin improves vascular cognitive impairment induced by ischemic stroke by remyelination via activation of ERK1/2 signaling and restoration of glutamatergic synapses in the gerbil hippocampus. ( Ahn, JH; Chen, BH; Hwang, IK; Kang, IJ; Kim, DW; Kim, YM; Lee, CH; Lee, JC; Lee, TK; Lee, YL; Park, JH; Won, MH; Yan, BC, 2018) |
| "Melatonin has demonstrated a potential protective effect in central nervous system." | 5.46 | Pre-ischemia melatonin treatment alleviated acute neuronal injury after ischemic stroke by inhibiting endoplasmic reticulum stress-dependent autophagy via PERK and IRE1 signalings. ( Abraham, N; Dong, Y; Feng, D; Huang, L; Qu, Y; Shi, W; Tao, K; Wang, B; Wang, L, 2017) |
| "Melatonin and aMT6S were measured by radioimmunoassay." | 5.35 | Nocturnal urine melatonin and 6-sulphatoxymelatonin excretion at the acute stage of ischaemic stroke. ( Berthiller, J; Brun, J; Cho, TH; Claustrat, B; Derex, L; Nighoghossian, N; Ritzenthaler, T; Schott, AM; Trouillas, P, 2009) |
| "Treatment with melatonin at 1." | 5.32 | Melatonin reduces nitric oxide level during ischemia but not blood-brain barrier breakdown during reperfusion in a rat middle cerebral artery occlusion stroke model. ( Cheung, RT; Fung, PC; Pei, Z, 2003) |
| "To assess an effect of melatonin on quality of life and effectiveness of rehabilitation in patients with ischemic stroke (IS) suffered from insomnia due to sleep initiation disturbance." | 5.20 | [Melatonin in the correction of sleep in post-stroke patients]. ( Davidov, NP; Ivanova, DS; Kuznetsov, AN; Vinogradov, OI, 2015) |
| " The purpose of this study was to evaluate the effect of fluvoxamine maleate, a selective serotonin re-uptake inhibitor (SSRI), on depressive state, sleep disturbance, and serum melatonin levels in patients with depressive state after cerebral infarction." | 5.16 | A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction. ( Katayama, Y; Katsura, K; Nishiyama, Y; Otori, T; Sunami, E; Usuda, K, 2012) |
| "Delivery of melatonin and targeting melatonin receptors pose as neuroprotective strategies for stroke therapy." | 4.91 | An update on the use of melatonin as a stroke therapeutic. ( Aguirre, D; Borlongan, CV; Gonzales-Portillo, GS; Kaneko, Y; Lozano, D; Reyes, S; Tajiri, N, 2015) |
| "The present review paper supports the approach to deliver melatonin and to target melatonin receptors for neuroprotection in stroke." | 4.89 | Melatonin-based therapeutics for neuroprotection in stroke. ( Borlongan, CV; Shinozuka, K; Staples, M, 2013) |
| "The data on the role of epiphysis and its key hormone melatonin in the natural mechanisms of brain protection from stroke are reviewed." | 4.85 | [Stroke and epiphysis]. ( Arushanian, EB; Naumov, SS, 2009) |
| "This article summarizes the evidence that endogenously produced and exogenously administered melatonin reduces the degree of tissue damage and limits the biobehavioral deficits associated with experimental models of ischemia/reperfusion injury in the brain (i." | 4.82 | When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. ( Kilic, E; Kilic, U; Leon, J; Reiter, RJ; Tan, DX, 2005) |
| "This review summarizes the numerous reports that have documented the neuroprotective actions of melatonin in experimental models of ischemia/reperfusion injury (stroke)." | 4.82 | Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke. ( Lopez-Burillo, S; Manchester, LC; Mayo, JC; Reiter, RJ; Sainz, RM; Tan, DX, 2003) |
| "Melatonin is a candidate neuroprotective drug for ischaemic stroke." | 4.82 | Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. ( Donnan, GA; Horky, LL; Howells, DW; Macleod, MR; O'Collins, T, 2005) |
| "Melatonin has a role in the cell survival signaling pathways as a candidate for secondary stroke prevention." | 4.12 | Delayed Therapeutic Administration of Melatonin Enhances Neuronal Survival Through AKT and MAPK Signaling Pathways Following Focal Brain Ischemia in Mice. ( Altug-Tasa, B; Beker, M; Beker, MC; Caglayan, AB; Elibol, B; Kilic, E; Kilic, U; Uysal, O; Yilmaz, B, 2022) |
| "Melatonin is a potent neuroprotective agent which has shown therapeutic effects in animal models of brain injury such as stroke." | 4.12 | Photothrombotic Mouse Models for the Study of Melatonin as a Therapeutic Tool After Ischemic Stroke. ( Cambiaghi, M; Cherchi, L; Comai, S, 2022) |
| "Consecutive patients admitted to the Tübingen University Stroke Unit, Tübingen, Germany, with acute ischemic stroke (AIS), who underwent standard care between August 2017 and December 2017, and patients who additionally received prophylactic melatonin (2 mg per day at night) within 24 h of symptom onset between August 2018 and December 2018 were included." | 4.02 | Delirium REduction after administration of melatonin in acute ischemic stroke (DREAMS): A propensity score-matched analysis. ( Boßelmann, C; Brendel, B; Fleischmann, R; Meisel, A; Mengel, A; Poli, S; Sartor-Pfeiffer, J; Stadler, V; Stefanou, MI; Ziemann, U; Zurloh, J, 2021) |
| "Previous literature has shown that melatonin plays a critical role in protecting against cerebral ischemia/reperfusion (I/R) injury." | 3.91 | Melatonin ameliorates cerebral ischemia/reperfusion injury through SIRT3 activation. ( Chen, H; Jin, J; Li, G; Liu, L; Tang, Z; Yin, P; Zhong, D, 2019) |
| "Objectives Lower serum melatonin levels are found in patients with ischaemic stroke compared with healthy controls." | 3.88 | Serum melatonin levels are associated with mortality in patients with malignant middle cerebral artery infarction. ( Abreu-González, P; Argueso, M; Cáceres, JJ; García-Marín, V; Jiménez, A; Lorente, L; Martín, MM; Pérez-Cejas, A; Ramos, L; Solé-Violán, J, 2018) |
| " In this study, we examined diurnal rhythmicity in different stages of Huntington (HD) disease and in patients with acute moderate ischemic stroke (AIS) outside the retinohypothalamic pathway by evaluating serum concentrations of melatonin and cortisol at twelve timepoints." | 3.85 | Circadian rhythms of melatonin and cortisol in manifest Huntington's disease and in acute cortical ischemic stroke. ( Adamczak-Ratajczak, A; Checinska-Maciejewska, Z; Gibas-Dorna, M; Krauss, H; Kupsz, J; Michalak, S; Owecki, M; Sowinska, A; Zielonka, D, 2017) |
| "In the acute phase of ischemic stroke 73 patients aged from 61 to 86 years and 47 patients aged 36 to 60 years underwent a comprehensive neuropsychological testing, evaluation of the concentration of 6-sulfatoximelatonin 6-sulfatoximelatonin in the night urine and brain MRI morphometry in some patients." | 3.83 | [The role of melatonin in the development of post-stroke cognitive impairment in elderly patients in comparison with middle-aged patients]. ( Drobakha, VE; Kulesh, AA; Shestakov, VV, 2016) |
| "To study disturbances of sleep and circadian rhythms in patients with cardiovascular diseases taking into account the level of melatonin secretion and to optimize a complex approach to their treatment." | 3.81 | [Sleep disorders and circadian rhythms in diseases of the cardiovascular system]. ( Eneeva, MA; Kamchatnov, PR; Kostenko, EV; Petrova, LV, 2015) |
| "To study melatonin secretion and its correlations with poststroke cognitive, emotional impairment and sleep quality in the acute period of stroke and to assess treatment efficacy of melaxen." | 3.80 | [Poststroke cognitive, emotional impairment and sleep quality: efficience of treatment with melaxen]. ( Kulesh, AA; Shestakov, VV, 2014) |
| "Melatonin at 60 min post ischemia rendered neuroprotection as evident by reduction in cerebral infarct volume, improvement in motor and neurological deficit and reduction in brain edema." | 3.80 | Melatonin renders neuroprotection by protein kinase C mediated aquaporin-4 inhibition in animal model of focal cerebral ischemia. ( Bhattacharya, P; Pandey, AK; Patnaik, R; Paul, S, 2014) |
| "Melatonin has many protective effects against ischemic stroke, but the underlying neuroprotective mechanisms are not fully understood." | 3.78 | Melatonin ameliorates neural function by promoting endogenous neurogenesis through the MT2 melatonin receptor in ischemic-stroke mice. ( Chern, CM; Liao, JF; Shen, YC; Wang, YH, 2012) |
| "The content of 6-sulfatoximelatonin in daily urine and butyrylcholinesterase in blood serum was determined in the acute stage of ischemic stroke in 25 and 40 men, respectively." | 3.78 | [Secretion of melatonin and serum cholinesterase activity as biological markers of cognitive disorders in the acute stage of ischemic stroke]. ( Kulesh, AA; Shestakov, VV, 2012) |
| "The efficacy of melatonin treatment in experimental stroke has been established." | 3.77 | Melatonin treatment following stroke induction modulates L-arginine metabolism. ( Appleton, I; Clarkson, AN; Nair, SM; Rahman, RM; Sammut, IA; Sutherland, BA; Taurin, S, 2011) |
| "Quantitative data on melatonin in stroke patients are scarce." | 3.75 | Impaired nocturnal melatonin in acute phase of ischaemic stroke: cross-sectional matched case-control analysis. ( Atanassova, PA; Dimitrov, BD; Terzieva, DD, 2009) |
| "Melatonin attenuates the short-term consequences of brain ischemia in several animal models." | 3.74 | Chronic and acute melatonin effects in gerbil global forebrain ischemia: long-term neural and behavioral outcome. ( de Butte, M; Fréchette, M; Pappas, BA; Rennie, K, 2008) |
| "Very little is known regarding melatonin's circadian rhythm in stroke patients." | 3.71 | Melatonin rhythms in stroke patients. ( Beloosesky, Y; Grinblat, J; Grosman, B; Laudon, M; Streifler, JY; Zisapel, N, 2002) |
| "Small doses of melatonin were administrated to 30 patients with day/night rhythm disorders, after cerebral stroke." | 3.70 | [Melatonin in sleep rhythm disorders after cerebral stroke]. ( Domzał, TM; Kaca-Oryńska, M; Zaleski, P, 2000) |
| "Melatonin was applied at a dose of 5 mg daily, one hour before sleep." | 2.75 | [Effect of melatonin on activity of superoxide dismutase (CuZn-SOD) in erythrocytes of patients during short- and long-term hypokinesis]. ( Garncarek, P; Kedziora, J; Malinowska, K; Miller, E; Mrowicka, M; Mrowicki, J; Smigielski, J, 2010) |
| "Ischemic stroke has remained a principal cause of mortality and neurological disabilities worldwide." | 2.72 | Effect of Melatonin on Endoplasmic Reticulum-Mitochondrial Crosstalk in Stroke. ( Abolhasanpour, N; Alihosseini, S; Badalzadeh, R; Golipourkhalili, S; Hosseini, L; Mahmoudi, J, 2021) |
| "Stroke is the second leading cause of death worldwide, estimated that one-sixth of the world population will suffer it once in their life." | 2.72 | Blood-brain barrier dysfunction in hemorrhagic transformation: a therapeutic opportunity for nanoparticles and melatonin. ( Caballero-Román, A; Escribano-Ferrer, E; Figueroa, EG; Fornaguera, C; García-Celma, MJ; González-Candia, A; Herrera, EA, 2021) |
| "Melatonin has been effectively used to combat oxidative stress, inflammation and cellular apoptosis and to restore tissue function in a number of human trials; its efficacy supports its more extensive use in a wider variety of human studies." | 2.53 | Melatonin as an antioxidant: under promises but over delivers. ( Alatorre-Jimenez, M; Mayo, JC; Qin, L; Reiter, RJ; Sainz, RM; Tan, DX, 2016) |
| " The recognition of the periodicity of biological processes makes the optimal dosing of certain drugs feasible." | 2.48 | [Physiological and pathophysiological role of the circadian clock system]. ( Halmos, T; Suba, I, 2012) |
| "Ischemic stroke is a leading cause of mortality and morbidity worldwide, with neuroinflammation playing a key role in its pathophysiology." | 1.91 | Melatonin regulates microglial polarization and protects against ischemic stroke-induced brain injury in mice. ( He, T; Li, D; Liu, J; Wang, D; Wang, Q; Yuan, Y; Zhang, S; Zhang, Y; Zhao, H, 2023) |
| "Melatonin has been shown to be neuroprotective in experimental stroke models." | 1.51 | Melatonin protects against ischemic stroke by modulating microglia/macrophage polarization toward anti-inflammatory phenotype through STAT3 pathway. ( Ding, ZT; Gao, FH; Gong, WJ; Liu, ZJ; Qie, SY; Ran, YY; Xi, JN, 2019) |
| "Melatonin was intraperitoneally administered to adult gerbils after transient global cerebral ischemia (tGCI) for 25 days beginning 5 days after tGCI." | 1.48 | Melatonin improves vascular cognitive impairment induced by ischemic stroke by remyelination via activation of ERK1/2 signaling and restoration of glutamatergic synapses in the gerbil hippocampus. ( Ahn, JH; Chen, BH; Hwang, IK; Kang, IJ; Kim, DW; Kim, YM; Lee, CH; Lee, JC; Lee, TK; Lee, YL; Park, JH; Won, MH; Yan, BC, 2018) |
| "Stroke is a major cause of acquired cerebral disability among adults, frequently accompanied by depression, anxiety, cognitive impairment, disrupted sleep and fatigue." | 1.46 | Impact of naturalistic lighting on hospitalized stroke patients in a rehabilitation unit: Design and measurement. ( Iversen, HK; Jennum, P; Pavlova, M; Sander, B; Simonsen, SA; West, A, 2017) |
| "Melatonin has demonstrated a potential protective effect in central nervous system." | 1.46 | Pre-ischemia melatonin treatment alleviated acute neuronal injury after ischemic stroke by inhibiting endoplasmic reticulum stress-dependent autophagy via PERK and IRE1 signalings. ( Abraham, N; Dong, Y; Feng, D; Huang, L; Qu, Y; Shi, W; Tao, K; Wang, B; Wang, L, 2017) |
| "Melatonin is a highly potent free radical scavenger that protects against ischemic stroke." | 1.42 | Effects of normobaric oxygen and melatonin on reperfusion injury: role of cerebral microcirculation. ( Beker, MC; Caglayan, AB; Caglayan, B; Hermann, DM; Kelestemur, T; Kilic, E; Kilic, U; Yalcin, E; Yulug, B, 2015) |
| "Melatonin and aMT6S were measured by radioimmunoassay." | 1.35 | Nocturnal urine melatonin and 6-sulphatoxymelatonin excretion at the acute stage of ischaemic stroke. ( Berthiller, J; Brun, J; Cho, TH; Claustrat, B; Derex, L; Nighoghossian, N; Ritzenthaler, T; Schott, AM; Trouillas, P, 2009) |
| "Treatment with melatonin at 1." | 1.32 | Melatonin reduces nitric oxide level during ischemia but not blood-brain barrier breakdown during reperfusion in a rat middle cerebral artery occlusion stroke model. ( Cheung, RT; Fung, PC; Pei, Z, 2003) |
| "Stroke is a major cause of brain injury in Alaska." | 1.31 | Melatonin exhibits antioxidant properties in a mouse brain slice model of excitotoxicity. ( Clapp-Lilly, KL; Drew, KL; Duffy, LK; Harris, PL; Perry, G; Smith, MA; Zhu, X, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (24.59) | 29.6817 |
| 2010's | 34 (55.74) | 24.3611 |
| 2020's | 12 (19.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zhong, X | 1 |
| Chen, B | 1 |
| Li, Z | 1 |
| Lin, R | 1 |
| Ruan, S | 1 |
| Wang, F | 1 |
| Liang, H | 1 |
| Tao, J | 1 |
| Kilic, U | 3 |
| Elibol, B | 1 |
| Caglayan, AB | 2 |
| Beker, MC | 2 |
| Beker, M | 1 |
| Altug-Tasa, B | 1 |
| Uysal, O | 1 |
| Yilmaz, B | 1 |
| Kilic, E | 5 |
| Azedi, F | 2 |
| Tavakol, S | 1 |
| Ketabforoush, AHME | 1 |
| Khazaei, G | 1 |
| Bakhtazad, A | 1 |
| Mousavizadeh, K | 2 |
| Joghataei, MT | 2 |
| Cambiaghi, M | 1 |
| Cherchi, L | 1 |
| Comai, S | 1 |
| Lu, D | 1 |
| Liu, Y | 1 |
| Huang, H | 1 |
| Hu, M | 1 |
| Li, T | 1 |
| Wang, S | 1 |
| Shen, S | 1 |
| Wu, R | 1 |
| Cai, W | 1 |
| Lu, T | 1 |
| Lu, Z | 1 |
| Mehrpooya, M | 1 |
| Mazdeh, M | 1 |
| Rahmani, E | 1 |
| Khazaie, M | 1 |
| Ahmadimoghaddam, D | 1 |
| Pawluk, H | 1 |
| Kołodziejska, R | 1 |
| Grześk, G | 1 |
| Woźniak, A | 1 |
| Kozakiewicz, M | 1 |
| Kosinska, A | 1 |
| Pawluk, M | 1 |
| Grzechowiak, E | 1 |
| Wojtasik, J | 1 |
| Kozera, G | 1 |
| Li, D | 1 |
| He, T | 1 |
| Zhang, Y | 1 |
| Liu, J | 1 |
| Zhao, H | 1 |
| Wang, D | 1 |
| Wang, Q | 1 |
| Yuan, Y | 1 |
| Zhang, S | 1 |
| Mehrpour, M | 1 |
| Talebi, S | 1 |
| Zendedel, A | 1 |
| Kazemnejad, S | 1 |
| Beyer, C | 1 |
| Zarnani, AH | 1 |
| Liu, L | 1 |
| Chen, H | 1 |
| Jin, J | 1 |
| Tang, Z | 1 |
| Yin, P | 1 |
| Zhong, D | 1 |
| Li, G | 1 |
| Liu, ZJ | 1 |
| Ran, YY | 1 |
| Qie, SY | 1 |
| Gong, WJ | 1 |
| Gao, FH | 1 |
| Ding, ZT | 1 |
| Xi, JN | 1 |
| Ramos, E | 2 |
| Farré-Alins, V | 1 |
| Egea, J | 2 |
| López-Muñoz, F | 1 |
| Reiter, RJ | 7 |
| Romero, A | 2 |
| Mengel, A | 1 |
| Zurloh, J | 1 |
| Boßelmann, C | 1 |
| Brendel, B | 1 |
| Stadler, V | 1 |
| Sartor-Pfeiffer, J | 1 |
| Meisel, A | 1 |
| Fleischmann, R | 1 |
| Ziemann, U | 1 |
| Poli, S | 1 |
| Stefanou, MI | 1 |
| Figueroa, EG | 1 |
| González-Candia, A | 1 |
| Caballero-Román, A | 1 |
| Fornaguera, C | 1 |
| Escribano-Ferrer, E | 1 |
| García-Celma, MJ | 1 |
| Herrera, EA | 1 |
| Abolhasanpour, N | 1 |
| Alihosseini, S | 1 |
| Golipourkhalili, S | 1 |
| Badalzadeh, R | 1 |
| Mahmoudi, J | 1 |
| Hosseini, L | 1 |
| West, A | 1 |
| Jennum, P | 1 |
| Simonsen, SA | 2 |
| Sander, B | 2 |
| Pavlova, M | 1 |
| Iversen, HK | 2 |
| Kulesh, AA | 4 |
| Drobakha, VE | 1 |
| Shestakov, VV | 4 |
| Yulug, B | 3 |
| Hanoglu, L | 1 |
| Adamczak-Ratajczak, A | 1 |
| Kupsz, J | 1 |
| Owecki, M | 1 |
| Zielonka, D | 1 |
| Sowinska, A | 1 |
| Checinska-Maciejewska, Z | 1 |
| Krauss, H | 1 |
| Michalak, S | 1 |
| Gibas-Dorna, M | 1 |
| Lorente, L | 1 |
| Martín, MM | 1 |
| Abreu-González, P | 1 |
| Pérez-Cejas, A | 1 |
| Ramos, L | 1 |
| Argueso, M | 1 |
| Solé-Violán, J | 1 |
| Cáceres, JJ | 1 |
| Jiménez, A | 1 |
| García-Marín, V | 1 |
| Chen, BH | 1 |
| Park, JH | 1 |
| Lee, YL | 1 |
| Kang, IJ | 1 |
| Kim, DW | 1 |
| Hwang, IK | 1 |
| Lee, CH | 1 |
| Yan, BC | 1 |
| Kim, YM | 1 |
| Lee, TK | 1 |
| Lee, JC | 1 |
| Won, MH | 1 |
| Ahn, JH | 1 |
| West, AS | 1 |
| Sennels, HP | 1 |
| Schønsted, M | 1 |
| Zielinski, AH | 1 |
| Hansen, NC | 1 |
| Jennum, PJ | 1 |
| Wolfram, F | 1 |
| Ritzenthaler, T | 2 |
| Lhommeau, I | 1 |
| Douillard, S | 1 |
| Cho, TH | 2 |
| Brun, J | 2 |
| Patrice, T | 1 |
| Nighoghossian, N | 2 |
| Claustrat, B | 3 |
| Shinozuka, K | 1 |
| Staples, M | 1 |
| Borlongan, CV | 4 |
| Bhattacharya, P | 1 |
| Pandey, AK | 1 |
| Paul, S | 1 |
| Patnaik, R | 1 |
| Gonzales-Portillo, GS | 1 |
| Lozano, D | 1 |
| Aguirre, D | 1 |
| Reyes, S | 2 |
| Tajiri, N | 1 |
| Kaneko, Y | 1 |
| Yang, Y | 1 |
| Jiang, S | 1 |
| Dong, Y | 2 |
| Fan, C | 1 |
| Zhao, L | 1 |
| Yang, X | 1 |
| Li, J | 1 |
| Di, S | 1 |
| Yue, L | 1 |
| Liang, G | 1 |
| Qu, Y | 2 |
| Lapaeva, TV | 1 |
| Kostenko, EV | 1 |
| Petrova, LV | 1 |
| Eneeva, MA | 1 |
| Kamchatnov, PR | 1 |
| Vinogradov, OI | 1 |
| Ivanova, DS | 1 |
| Davidov, NP | 1 |
| Kuznetsov, AN | 1 |
| Kelestemur, T | 1 |
| Caglayan, B | 1 |
| Yalcin, E | 1 |
| Hermann, DM | 1 |
| Watson, N | 1 |
| Diamandis, T | 1 |
| Gonzales-Portillo, C | 1 |
| Wolf, K | 1 |
| Braun, A | 1 |
| Haining, EJ | 1 |
| Tseng, YL | 1 |
| Kraft, P | 1 |
| Schuhmann, MK | 1 |
| Gotru, SK | 1 |
| Chen, W | 1 |
| Hermanns, HM | 1 |
| Stoll, G | 1 |
| Lesch, KP | 1 |
| Nieswandt, B | 1 |
| Mayo, JC | 2 |
| Tan, DX | 4 |
| Sainz, RM | 2 |
| Alatorre-Jimenez, M | 1 |
| Qin, L | 1 |
| Patiño, P | 1 |
| Gil-Martín, E | 1 |
| Marco-Contelles, J | 1 |
| Parada, E | 1 |
| de Los Rios, C | 1 |
| Wu, HJ | 1 |
| Wu, C | 1 |
| Niu, HJ | 1 |
| Wang, K | 1 |
| Mo, LJ | 1 |
| Shao, AW | 1 |
| Dixon, BJ | 1 |
| Zhang, JM | 1 |
| Yang, SX | 1 |
| Wang, YR | 1 |
| Feng, D | 1 |
| Wang, B | 1 |
| Wang, L | 1 |
| Abraham, N | 1 |
| Tao, K | 1 |
| Huang, L | 1 |
| Shi, W | 1 |
| Cam, E | 1 |
| Cengiz, N | 1 |
| Poelkin, E | 1 |
| Isýk, D | 1 |
| Bakar, M | 1 |
| Ozan, E | 1 |
| Berthiller, J | 1 |
| Schott, AM | 1 |
| Derex, L | 1 |
| Trouillas, P | 1 |
| Atanassova, PA | 1 |
| Terzieva, DD | 1 |
| Dimitrov, BD | 1 |
| Mrowicka, M | 1 |
| Garncarek, P | 1 |
| Miller, E | 1 |
| Kedziora, J | 1 |
| Smigielski, J | 1 |
| Malinowska, K | 1 |
| Mrowicki, J | 1 |
| Arushanian, EB | 2 |
| Naumov, SS | 2 |
| O'Collins, VE | 1 |
| Macleod, MR | 2 |
| Cox, SF | 1 |
| Van Raay, L | 1 |
| Aleksoska, E | 1 |
| Donnan, GA | 2 |
| Howells, DW | 2 |
| Nair, SM | 1 |
| Rahman, RM | 1 |
| Clarkson, AN | 1 |
| Sutherland, BA | 1 |
| Taurin, S | 1 |
| Sammut, IA | 1 |
| Appleton, I | 1 |
| Chern, CM | 1 |
| Liao, JF | 1 |
| Wang, YH | 1 |
| Shen, YC | 1 |
| Sunami, E | 1 |
| Usuda, K | 1 |
| Nishiyama, Y | 1 |
| Otori, T | 1 |
| Katsura, K | 1 |
| Katayama, Y | 1 |
| Halmos, T | 1 |
| Suba, I | 1 |
| Pei, Z | 1 |
| Fung, PC | 1 |
| Cheung, RT | 1 |
| Sumaya, I | 1 |
| Moss, D | 1 |
| Kumazaki, M | 1 |
| Sakurai, T | 1 |
| Hida, H | 1 |
| Nishino, H | 1 |
| Lopez-Burillo, S | 1 |
| Manchester, LC | 2 |
| O'Collins, T | 1 |
| Horky, LL | 1 |
| Leon, J | 1 |
| Tamura, H | 1 |
| Rennie, K | 1 |
| de Butte, M | 1 |
| Fréchette, M | 1 |
| Pappas, BA | 1 |
| Domzał, TM | 1 |
| Kaca-Oryńska, M | 1 |
| Zaleski, P | 1 |
| Beloosesky, Y | 1 |
| Grinblat, J | 1 |
| Laudon, M | 1 |
| Grosman, B | 1 |
| Streifler, JY | 1 |
| Zisapel, N | 1 |
| Clapp-Lilly, KL | 1 |
| Smith, MA | 1 |
| Perry, G | 1 |
| Harris, PL | 1 |
| Zhu, X | 1 |
| Drew, KL | 1 |
| Duffy, LK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Sunlight Improves Depression in Stroke Patients[NCT04036565] | 46 participants (Actual) | Observational [Patient Registry] | 2017-10-09 | Completed | |||
| Use of Melatonin for Neuroprotection in Term Infants With Hypoxic-ischaemic Encephalopathy[NCT03806816] | 100 participants (Anticipated) | Interventional | 2018-12-13 | Recruiting | |||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Agomelatine in the Prevention of Poststroke Depression[NCT05426304] | Phase 4 | 420 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for melatonin and Stroke
| Article | Year |
|---|---|
Modulation of autophagy by melatonin via sirtuins in stroke: From mechanisms to therapies.
Topics: Antioxidants; Apoptosis; Autophagy; Humans; Melatonin; Oxidative Stress; Sirtuins; Stroke | 2022 |
Melatonin's efficacy in stroke patients; a matter of dose? A systematic review.
Topics: Dose-Response Relationship, Drug; Humans; Melatonin; Stroke | 2020 |
Blood-brain barrier dysfunction in hemorrhagic transformation: a therapeutic opportunity for nanoparticles and melatonin.
Topics: Blood-Brain Barrier; Cerebral Hemorrhage; Humans; Melatonin; Nanoparticles; Neuroprotective Agents; | 2021 |
Effect of Melatonin on Endoplasmic Reticulum-Mitochondrial Crosstalk in Stroke.
Topics: Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Humans; Melatonin; Mitochondria; Stroke | 2021 |
Melatonin-based therapeutics for neuroprotection in stroke.
Topics: Animals; Clinical Trials as Topic; Humans; Melatonin; Neuroprotective Agents; Pineal Gland; Stem Cel | 2013 |
An update on the use of melatonin as a stroke therapeutic.
Topics: Clinical Trials as Topic; Humans; Melatonin; Receptors, Melatonin; Stroke | 2015 |
Melatonin as an Antioxidant for Stroke Neuroprotection.
Topics: Animals; Antioxidants; Catechin; Cell- and Tissue-Based Therapy; Humans; Melatonin; Neuroprotection; | 2016 |
Melatonin as an antioxidant: under promises but over delivers.
Topics: Animals; Antioxidants; Apoptosis; Humans; Melatonin; Myocardial Reperfusion Injury; Oxidative Stress | 2016 |
Ischemic brain injury: New insights on the protective role of melatonin.
Topics: Antioxidants; Blood-Brain Barrier; Brain Ischemia; Calcium; Humans; Melatonin; Neuroprotective Agent | 2017 |
Neuroprotective Mechanisms of Melatonin in Hemorrhagic Stroke.
Topics: Animals; Cerebral Hemorrhage; Humans; Melatonin; Neuroprotective Agents; Signal Transduction; Stroke | 2017 |
[Stroke and epiphysis].
Topics: Aged; Brain Ischemia; Circadian Rhythm; Humans; Melatonin; Pineal Gland; Stroke | 2009 |
Preclinical drug evaluation for combination therapy in acute stroke using systematic review, meta-analysis, and subsequent experimental testing.
Topics: Age Factors; Animals; Drug Evaluation, Preclinical; Drug Interactions; Drug Therapy, Combination; Ma | 2011 |
[Physiological and pathophysiological role of the circadian clock system].
Topics: Aging; ARNTL Transcription Factors; Blood Coagulation Disorders; Cardiovascular Diseases; Circadian | 2012 |
Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke.
Topics: Animals; Antioxidants; Brain; Brain Ischemia; Disease Models, Animal; Humans; Melatonin; Neuroprotec | 2003 |
Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke.
Topics: Animals; Disease Models, Animal; Melatonin; Neuroprotective Agents; Stroke | 2005 |
When melatonin gets on your nerves: its beneficial actions in experimental models of stroke.
Topics: Animals; Antioxidants; DNA Damage; Humans; Lipid Peroxidation; Melatonin; Models, Biological; Models | 2005 |
[Disruptions of circadian rhythm in neurologic disorders].
Topics: Autonomic Nervous System Diseases; Body Temperature Regulation; Brain Neoplasms; Central Nervous Sys | 2006 |
Melatonin defeats neurally-derived free radicals and reduces the associated neuromorphological and neurobehavioral damage.
Topics: Animals; Antioxidants; Free Radical Scavengers; Free Radicals; Head Injuries, Closed; Humans; Melato | 2007 |
6 trials available for melatonin and Stroke
| Article | Year |
|---|---|
Melatonin supplementation may benefit patients with acute ischemic stroke not eligible for reperfusion therapies: Results of a pilot study.
Topics: Brain Ischemia; Dietary Supplements; Double-Blind Method; Humans; Ischemic Stroke; Melatonin; Pilot | 2022 |
The Effects of Naturalistic Light on Diurnal Plasma Melatonin and Serum Cortisol Levels in Stroke Patients during Admission for Rehabilitation: A Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Circadian Rhythm; Cohort Studies; Female; Hospitalization; Humans; Hydrocor | 2019 |
[Chronobiological characteristics of stroke and poststroke cognitive impairment].
Topics: Adult; Aged; Brain Ischemia; Circadian Rhythm; Cognition; Female; Humans; Male; Melatonin; Middle Ag | 2014 |
[Melatonin in the correction of sleep in post-stroke patients].
Topics: Aged; Female; Humans; Male; Melatonin; Middle Aged; Polysomnography; Quality of Life; Sleep Initiati | 2015 |
[Effect of melatonin on activity of superoxide dismutase (CuZn-SOD) in erythrocytes of patients during short- and long-term hypokinesis].
Topics: Administration, Oral; Aged; Drug Administration Schedule; Erythrocyte Count; Erythrocytes; Humans; H | 2010 |
A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cerebral Infarction; Depression; | 2012 |
37 other studies available for melatonin and Stroke
| Article | Year |
|---|---|
Electroacupuncture Ameliorates Cognitive Impairment Through the Inhibition of NLRP3 Inflammasome Activation by Regulating Melatonin-Mediated Mitophagy in Stroke Rats.
Topics: Animals; Brain Ischemia; Cognitive Dysfunction; Electroacupuncture; Infarction, Middle Cerebral Arte | 2022 |
Delayed Therapeutic Administration of Melatonin Enhances Neuronal Survival Through AKT and MAPK Signaling Pathways Following Focal Brain Ischemia in Mice.
Topics: Animals; Brain Ischemia; Cell Survival; Melatonin; Mice; Proto-Oncogene Proteins c-akt; Signal Trans | 2022 |
Photothrombotic Mouse Models for the Study of Melatonin as a Therapeutic Tool After Ischemic Stroke.
Topics: Animals; Brain Injuries; Brain Ischemia; Disease Models, Animal; Humans; Ischemic Stroke; Melatonin; | 2022 |
Melatonin Offers Dual-Phase Protection to Brain Vessel Endothelial Cells in Prolonged Cerebral Ischemia-Recanalization Through Ameliorating ER Stress and Resolving Refractory Stress Granule.
Topics: Animals; Brain; Brain Ischemia; Cerebral Infarction; Endothelial Cells; Ischemic Stroke; Melatonin; | 2023 |
Increased Oxidative Stress Markers in Acute Ischemic Stroke Patients Treated with Thrombolytics.
Topics: Antioxidants; Fibrinolytic Agents; Humans; Ischemic Stroke; Melatonin; Oxidation-Reduction; Oxidativ | 2022 |
Melatonin regulates microglial polarization and protects against ischemic stroke-induced brain injury in mice.
Topics: Animals; Brain Injuries; Brain Ischemia; Infarction, Middle Cerebral Artery; Ischemic Stroke; Melato | 2023 |
Melatonin regulates neuroinflammation ischemic stroke damage through interactions with microglia in reperfusion phase.
Topics: Animals; Brain Ischemia; Inflammation; Ischemia; Male; Melatonin; Microglia; Neuroimmunomodulation; | 2019 |
Melatonin ameliorates cerebral ischemia/reperfusion injury through SIRT3 activation.
Topics: Animals; Apoptosis; Brain Ischemia; Infarction, Middle Cerebral Artery; Male; Melatonin; Mice; Mice, | 2019 |
Melatonin protects against ischemic stroke by modulating microglia/macrophage polarization toward anti-inflammatory phenotype through STAT3 pathway.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Brain Ischemia; Cell Hypoxia; Cell Line | 2019 |
Delirium REduction after administration of melatonin in acute ischemic stroke (DREAMS): A propensity score-matched analysis.
Topics: Brain Ischemia; Delirium; Humans; Ischemic Stroke; Melatonin; Propensity Score; Prospective Studies; | 2021 |
Impact of naturalistic lighting on hospitalized stroke patients in a rehabilitation unit: Design and measurement.
Topics: Adult; Aged; Circadian Rhythm; Cognition; Fatigue; Female; Humans; Light; Male; Melatonin; Middle Ag | 2017 |
[The role of melatonin in the development of post-stroke cognitive impairment in elderly patients in comparison with middle-aged patients].
Topics: Age Factors; Aged; Aged, 80 and over; Cognition; Cognitive Dysfunction; Female; Hippocampus; Humans; | 2016 |
Commentary: Toward a Personalized Medicine in Wake-Up Stroke?
Topics: Circadian Rhythm; Circadian Rhythm Signaling Peptides and Proteins; Humans; Melatonin; Precision Med | 2017 |
Circadian rhythms of melatonin and cortisol in manifest Huntington's disease and in acute cortical ischemic stroke.
Topics: Brain Ischemia; Circadian Rhythm; Humans; Huntington Disease; Hydrocortisone; Male; Melatonin; Middl | 2017 |
Serum melatonin levels are associated with mortality in patients with malignant middle cerebral artery infarction.
Topics: Aged; Antioxidants; Female; Humans; Infarction, Middle Cerebral Artery; Malondialdehyde; Melatonin; | 2018 |
Melatonin improves vascular cognitive impairment induced by ischemic stroke by remyelination via activation of ERK1/2 signaling and restoration of glutamatergic synapses in the gerbil hippocampus.
Topics: Animals; Brain-Derived Neurotrophic Factor; CA1 Region, Hippocampal; Cell Death; Cognitive Dysfuncti | 2018 |
Dynamics of oxidative stress and urinary excretion of melatonin and its metabolites during acute ischemic stroke.
Topics: Aged; Comorbidity; Female; France; Humans; Ischemia; Male; Melatonin; Metabolism; Middle Aged; Oxida | 2013 |
Melatonin renders neuroprotection by protein kinase C mediated aquaporin-4 inhibition in animal model of focal cerebral ischemia.
Topics: Animals; Antioxidants; Apoptosis; Aquaporin 4; Blotting, Western; Brain Edema; Brain Ischemia; Calci | 2014 |
[Poststroke cognitive, emotional impairment and sleep quality: efficience of treatment with melaxen].
Topics: Adult; Aged; Anxiety; Cognition; Cognition Disorders; Emotions; Female; Humans; Male; Melatonin; Mid | 2014 |
Melatonin prevents cell death and mitochondrial dysfunction via a SIRT1-dependent mechanism during ischemic-stroke in mice.
Topics: Animals; Antioxidants; Brain Ischemia; Carbazoles; Cell Death; Male; Melatonin; Mice; Mitochondria; | 2015 |
[Sleep disorders and circadian rhythms in diseases of the cardiovascular system].
Topics: Aged; Cardiovascular Diseases; Circadian Rhythm; Cognition Disorders; Female; Humans; Male; Melatoni | 2015 |
Effects of normobaric oxygen and melatonin on reperfusion injury: role of cerebral microcirculation.
Topics: Animals; Antioxidants; bcl-2-Associated X Protein; bcl-X Protein; Blood-Brain Barrier; Brain; Brain | 2015 |
Partially Defective Store Operated Calcium Entry and Hem(ITAM) Signaling in Platelets of Serotonin Transporter Deficient Mice.
Topics: Animals; Blood Platelets; Calcium; Disease Models, Animal; Fibrinogen; Hemostasis; Hydroxyindoleacet | 2016 |
Pre-ischemia melatonin treatment alleviated acute neuronal injury after ischemic stroke by inhibiting endoplasmic reticulum stress-dependent autophagy via PERK and IRE1 signalings.
Topics: Animals; Autophagy; Brain Ischemia; eIF-2 Kinase; Endoplasmic Reticulum Stress; Male; Melatonin; Mem | 2017 |
Melatonin: a suitable agent for depression associated with stroke?
Topics: Animals; Antioxidants; Cerebral Infarction; Depressive Disorder; Humans; Ischemic Attack, Transient; | 2008 |
Nocturnal urine melatonin and 6-sulphatoxymelatonin excretion at the acute stage of ischaemic stroke.
Topics: Adolescent; Age Factors; Aged; Brain Ischemia; Chi-Square Distribution; Circadian Rhythm; Female; Hu | 2009 |
Impaired nocturnal melatonin in acute phase of ischaemic stroke: cross-sectional matched case-control analysis.
Topics: Brain Ischemia; Case-Control Studies; Creatinine; Cross-Sectional Studies; Female; Humans; Hydrocort | 2009 |
Melatonin treatment following stroke induction modulates L-arginine metabolism.
Topics: Animals; Arginine; Blotting, Western; Cell Line, Tumor; Disease Models, Animal; Humans; Male; Melato | 2011 |
Melatonin ameliorates neural function by promoting endogenous neurogenesis through the MT2 melatonin receptor in ischemic-stroke mice.
Topics: Animals; Base Sequence; Brain Ischemia; DNA Primers; Immunohistochemistry; Melatonin; Mice; Neurogen | 2012 |
[Influence of pineal hormone melatonin on behavioral disturbances and neurological status of animals after hemorrhagic stroke].
Topics: Animals; Behavior, Animal; Circadian Rhythm; Intracranial Hemorrhages; Melatonin; Neuroprotective Ag | 2011 |
[Secretion of melatonin and serum cholinesterase activity as biological markers of cognitive disorders in the acute stage of ischemic stroke].
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Butyrylcholinesterase; Cognition Disorders; Humans; Male | 2012 |
Melatonin reduces nitric oxide level during ischemia but not blood-brain barrier breakdown during reperfusion in a rat middle cerebral artery occlusion stroke model.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Disease Models, Animal; Electron Spin Resonance Spectr | 2003 |
Melatonin-secreting pineal gland: a novel tissue source for neural transplantation therapy in stroke.
Topics: Animals; Behavior, Animal; Cell Transplantation; Cerebrovascular Circulation; Infarction, Middle Cer | 2003 |
Chronic and acute melatonin effects in gerbil global forebrain ischemia: long-term neural and behavioral outcome.
Topics: Animals; Behavior, Animal; Brain Ischemia; Cell Count; Cell Differentiation; Disease Models, Animal; | 2008 |
[Melatonin in sleep rhythm disorders after cerebral stroke].
Topics: Aged; Aged, 80 and over; Antioxidants; Female; Humans; Male; Melatonin; Middle Aged; Sleep Disorders | 2000 |
Melatonin rhythms in stroke patients.
Topics: Age Factors; Aged; Brain; Cell Survival; Circadian Rhythm; Female; Humans; Male; Melatonin; Neuropro | 2002 |
Melatonin exhibits antioxidant properties in a mouse brain slice model of excitotoxicity.
Topics: Animals; Antioxidants; Brain; Excitatory Amino Acid Antagonists; In Vitro Techniques; Melatonin; Mic | 2002 |